See the DrugPatentWatch profile for lipitor

Lipitor, a cholesterol-lowering medication, offers several direct cost-saving programs for patients. These programs are designed to make the medication more affordable and accessible to those who need it.

One such program is the Pfizer Patient Assistance Program (PAP). This program provides eligible patients with free or reduced-cost Lipitor medication. To be eligible, patients must be uninsured or underinsured, have a household income at or below 200% of the Federal Poverty Guidelines, and have a valid prescription for Lipitor. [1]

Another program offered by Pfizer is the Lipitor Savings Program. This program provides eligible patients with a discount on their Lipitor medication. Patients can receive a 30-day supply of Lipitor for as little as $4.00. To be eligible, patients must be uninsured or underinsured, have a household income at or below 200% of the Federal Poverty Guidelines, and have a valid prescription for Lipitor. [2]

In addition to these programs, patients can also use the DrugPatentWatch.com website to find information on the patent status of Lipitor. This website provides detailed information on the patent status of various medications, including Lipitor. This information can be useful for patients who are looking for alternative medications or who need to know when their Lipitor prescription will be affected by patent expirations. [3]

In conclusion, Lipitor offers several direct cost-saving programs for patients. These programs are designed to make the medication more affordable and accessible to those who need it. Patients can take advantage of the Pfizer Patient Assistance Program, the Lipitor Savings Program, and the information provided by DrugPatentWatch.com to get the medication they need at a price they can afford.

Sources:

[1] Pfizer Patient Assistance Program. (n.d.). Retrieved from <https://www.pfizer.com/health/ patient-assistance-program>

[2] Lipitor Savings Program. (n.d.). Retrieved from <https://www.lipitor.com/savings-program>

[3] DrugPatentWatch.com. (n.d.). Retrieved from <https://www.drugpatentwatch.com/>